{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:40:49Z","timestamp":1793972449181,"version":"4.8.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ijbiomac.2024.131324","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T22:17:29Z","timestamp":1712182649000},"page":"131324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"P1","title":["An unprecedented global challenge, emerging trends and innovations in the fight against COVID-19: A comprehensive review"],"prefix":"10.1016","volume":"267","author":[{"given":"S.","family":"Moneshwaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Macrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kanagathara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0005","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Bio-medica\u00a0: Atenei Parmensis"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0010","author":"World Health Organization"},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.131324_bb0015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","article-title":"A global database of COVID-19 vaccinations","volume":"5","author":"Mathieu","year":"2021","journal-title":"Nat. Hum. Behav."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.131324_bb0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jmv.25688","article-title":"The 2019-new coronavirus epidemic: evidence for virus evolution","volume":"92","author":"Benvenuto","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0025","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.131324_bb0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jmii.2020.03.022","article-title":"Genotype and phenotype of COVID-19: their roles in pathogenesis. Journal of microbiology, immunology, and infection =","volume":"54","author":"Mousavizadeh","year":"2021","journal-title":"Wei mian yu gan ran za zhi"},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.131324_bb0035","first-page":"26","article-title":"Human coronaviruses: A review of virus-host interactions","volume":"4","author":"Lim","year":"2016","journal-title":"Diseases (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0040","first-page":"8","article-title":"Coronavirus: A Mini-review","volume":"6","author":"Syed","year":"2020","journal-title":"Int. J. Curr. Res. Med. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.131324_bb0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3201\/eid1002.030913","article-title":"Ultrastructural characterization of SARS coronavirus","volume":"10","author":"Goldsmith","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2014.06.013","article-title":"Accessory proteins of SARS-CoV and other coronaviruses","volume":"109","author":"Liu","year":"2014","journal-title":"Antivir. Res."},{"issue":"February 22","key":"10.1016\/j.ijbiomac.2024.131324_bb0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395, no. 10224","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0065","author":"Worldometer COVID-19 coronavirus pandemic"},{"issue":"42","key":"10.1016\/j.ijbiomac.2024.131324_bb0070","doi-asserted-by":"crossref","first-page":"11157","DOI":"10.1073\/pnas.1708727114","article-title":"Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion","volume":"114","author":"Walls","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.131324_bb0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0165-6147(00)01994-5","article-title":"The angiotensin-converting enzyme gene family: genomics and pharmacology","volume":"23","author":"Turner","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.131324_bb0080","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"issue":"6891","key":"10.1016\/j.ijbiomac.2024.131324_bb0085","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"issue":"43","key":"10.1016\/j.ijbiomac.2024.131324_bb0090","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"7798","key":"10.1016\/j.ijbiomac.2024.131324_bb0095","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.131324_bb0100","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0105","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","article-title":"The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex","volume":"77","author":"Bosch","year":"2003","journal-title":"J. Virol."},{"issue":"7871","key":"10.1016\/j.ijbiomac.2024.131324_bb0110","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"issue":"10293","key":"10.1016\/j.ijbiomac.2024.131324_bb0115","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0120","doi-asserted-by":"crossref","first-page":"L84","DOI":"10.1152\/ajplung.00071.2009","article-title":"Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia","volume":"297","author":"Jia","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.131324_bb0125","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/JVI.02202-13","article-title":"TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome corona virus spike protein","volume":"88","author":"Heurich","year":"2014","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.131324_bb0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"July 14","key":"10.1016\/j.ijbiomac.2024.131324_bb0135","article-title":"The SARS-CoV-2 Main protease (M pro): structure, function, and emerging therapies for COVID-19","volume":"3, no. 3","author":"Hu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0140","series-title":"StatPearls","article-title":"Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)","author":"Aleem","year":"2023"},{"issue":"April 4","key":"10.1016\/j.ijbiomac.2024.131324_bb0145","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1002\/jmv.27757","article-title":"Variant-specific SARS-CoV-2 within-host kinetics","volume":"94, no. 8","author":"Elie","year":"2022","journal-title":"J. Med. Virol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.131324_bb0150","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1053\/j.jvca.2020.10.019","article-title":"Myocardial injury on admission as a risk in critically ill COVID-19 patients: A retrospective in-ICU study","volume":"35","author":"Qian","year":"2021","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"issue":"January 1","key":"10.1016\/j.ijbiomac.2024.131324_bb0155","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.7150\/ijbs.69677","article-title":"Manifestations and mechanism of SARS-CoV2 mediated cardiac injury","volume":"18, no. 7","author":"Xu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0160","article-title":"Coronavirus disease 2019 and cardiovascular system: A narrative review","volume":"29","author":"Kwenandar","year":"2020","journal-title":"International journal of cardiology. Heart & vasculature"},{"issue":"August 28","key":"10.1016\/j.ijbiomac.2024.131324_bb0165","first-page":"1453","article-title":"Kidney implications of SARS-CoV2 infection in children","volume":"37, no. 7","author":"Bjornstad","year":"2021","journal-title":"Pediatr. Nephrol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.131324_bb0170","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00134-020-06153-9","article-title":"Acute kidney injury in critically ill patients with COVID-19","volume":"46","author":"Gabarre","year":"2020","journal-title":"Intensive Care Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.131324_bb0175","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/j.ajkd.2020.12.007","article-title":"The association of COVID-19 with acute kidney injury independent of severity of illness: A multicenter cohort study","volume":"77","author":"Moledina","year":"2021","journal-title":"Am. J. Kidney Dis."},{"issue":"9","key":"10.1016\/j.ijbiomac.2024.131324_bb0180","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1681\/ASN.2020040509","article-title":"AKI in hospitalized patients with and without COVID-19: A comparison study","volume":"31","author":"Fisher","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0185","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.ajkd.2020.10.001","article-title":"Multicenter clinicopathologic correlation of kidney biopsies performed in COVID-19 patients presenting with acute kidney injury or proteinuria","volume":"77","author":"Akilesh","year":"2021","journal-title":"Am. J. Kidney Dis."},{"issue":"February 7","key":"10.1016\/j.ijbiomac.2024.131324_bb0190","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"28, no. 3","author":"Xie","year":"2022","journal-title":"Nat. Med."},{"issue":"January 18","key":"10.1016\/j.ijbiomac.2024.131324_bb0195","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591, no. 7851","author":"Gaebler","year":"2021","journal-title":"Nature"},{"issue":"April 14","key":"10.1016\/j.ijbiomac.2024.131324_bb0200","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41379-020-0536-x","article-title":"Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies","volume":"33, no. 6","author":"Tian","year":"2020","journal-title":"Mod. Pathol."},{"issue":"March 31","key":"10.1016\/j.ijbiomac.2024.131324_bb0205","article-title":"Post-Covid syndrome in individuals admitted to hospital with Covid-19: retrospective cohort study","volume":"n693","author":"Ayoubkhani","year":"2021","journal-title":"BMJ"},{"issue":"November 2","key":"10.1016\/j.ijbiomac.2024.131324_bb0210","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s11886-022-01793-3","article-title":"Cardiac Manifesta- tions of post-acute COVID-19 infection","volume":"24, no. 12","author":"Mohammad","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.131324_bb0215","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1473-3099(20)30434-5","article-title":"Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-Centre descriptive study","volume":"20","author":"Carsana","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.131324_bb0220","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00414-020-02390-1","article-title":"Complete post-mortem data in a fatal case of COVID-19: clinical, radiological and pathological correlations","volume":"134","author":"Ducloyer","year":"2020","journal-title":"Int. J. Legal Med."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.131324_bb0225","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.chest.2019.10.032","article-title":"Viral infection increases the risk of idiopathic pulmonary fibrosis: A Meta-analysis","volume":"157","author":"Sheng","year":"2020","journal-title":"Chest"},{"issue":"December 1","key":"10.1016\/j.ijbiomac.2024.131324_bb0230","first-page":"693","article-title":"Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the UKILD post\u2013COVID-19 study","volume":"207, no. 6","author":"Stewart","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.131324_bb0235","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA neurology"},{"issue":"23","key":"10.1016\/j.ijbiomac.2024.131324_bb0240","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMc2008597","article-title":"Neurologic features in severe SARS-CoV-2 infection","volume":"382","author":"Helms","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.131324_bb0245","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"10229","key":"10.1016\/j.ijbiomac.2024.131324_bb0250","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"16","key":"10.1016\/j.ijbiomac.2024.131324_bb0255","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1001\/jama.2010.1553","article-title":"Long-term cognitive impairment and functional disability among survivors of severe sepsis","volume":"304","author":"Iwashyna","year":"2010","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.131324_bb0260","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1474-4422(14)70017-1","article-title":"Long-term cerebral consequences of sepsis","volume":"13","author":"Widmann","year":"2014","journal-title":"The Lancet. Neurology"},{"issue":"9 September 28","key":"10.1016\/j.ijbiomac.2024.131324_bb0265","article-title":"Incidence, Co-Occurrence, and Evolution of Long-COVID Features: A 6-Month Retrospective Cohort Study of 273,618 Survivors of COVID-19","volume":"18","author":"Taquet","year":"2021","journal-title":"PLoS Med."},{"issue":"June 4","key":"10.1016\/j.ijbiomac.2024.131324_bb0270","article-title":"Immediate and long-term consequences of COVID-19 infections for the development of neurological disease","volume":"12, no. 1","author":"Heneka","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0275","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3012778","article-title":"Exploring the paradox of COVID-19 in neurological complications with emphasis on Parkinson\u2019s and Alzheimer\u2019s disease","volume":"2022","author":"Rai","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-020-01904-3","article-title":"Neurocognitive impacts of arbovirus infections","volume":"17","author":"Cl\u00e9","year":"2020","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0285","first-page":"1","article-title":"Arbovirus and seizures","volume":"2","author":"Zheng","year":"2020","journal-title":"Acta Epileptologica"},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.131324_bb0290","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jmv.25915","article-title":"Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)","volume":"92","author":"Paniz-Mondolfi","year":"2020","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0295","first-page":"1","article-title":"SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.131324_bb0300","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41593-020-00771-8","article-title":"The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice","volume":"24","author":"Rhea","year":"2021","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.131324_bb0305","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV--a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"issue":"April 6","key":"10.1016\/j.ijbiomac.2024.131324_bb0310","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.2021.3199","article-title":"SARS-CoV-2 vaccines","volume":"325, no. 13","author":"Creech","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.131324_bb0315","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"issue":"January 1","key":"10.1016\/j.ijbiomac.2024.131324_bb0320","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(21)00460-6","article-title":"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: A prospective, community-based, nested, case-control study","volume":"22, no. 1","author":"Antonelli","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0325","article-title":"SIREN protocol: Impact of detectable anti-SARS-CoV-2 on the subsequent incidence of COVID-19 in 100,000 healthcare workers: Do antibody positive healthcare workers have less reinfection than antibody negative healthcare workers?","volume":"December 18","author":"Wallace","year":"2020","journal-title":"MedRxiv (Cold Spring Harbor Laboratory)"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0330","series-title":"Immunoinformatics","first-page":"185","article-title":"Prediction of peptide-MHC binding using profiles","author":"Reche","year":"2007"},{"issue":"October 13","key":"10.1016\/j.ijbiomac.2024.131324_bb0335","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1080\/07391102.2020.1787227","article-title":"Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach","volume":"39, no. 15","author":"Bhatnager","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"February 16","key":"10.1016\/j.ijbiomac.2024.131324_bb0340","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386, no. 13","author":"Hall","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"issue":"22","key":"10.1016\/j.ijbiomac.2024.131324_bb0350","doi-asserted-by":"crossref","first-page":"11440","DOI":"10.1128\/JVI.76.22.11440-11446.2002","article-title":"Inhibition of endosomal\/lysosomal degradation increases the infectivity of human immunodeficiency virus","volume":"76","author":"Fredericksen","year":"2002","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.131324_bb0355","first-page":"102","article-title":"Mechanism and adverse effects of COVID-19 drugs: a basic review","volume":"13","author":"Zadeh","year":"2021","journal-title":"PubMed Central (PMC)"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0360","article-title":"Chloroquine and hydroxychloroquine in covid-19","volume":"m1432","author":"Ferner","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0365","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharma- cologic treatments for coronavirus disease 2019 (COVID-19)","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.131324_bb0370","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3904\/kjim.2020.157","article-title":"In vitro activity of lopinavir\/ritonavir and hydroxychloro- quine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses","volume":"35","author":"Kang","year":"2020","journal-title":"Korean J. Intern. Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.131324_bb0375","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3904\/kjim.2020.157","article-title":"In vitro activity of lopinavir\/ritonavir and hydroxychloro- quine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses","volume":"35","author":"Kang","year":"2020","journal-title":"Korean J. Intern. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.131324_bb0380","first-page":"215","article-title":"A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19","volume":"49","author":"Chen","year":"2020","journal-title":"PubMed"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.131324_bb0385","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00970-21","article-title":"The TMPRSS2 inhibitor nafamostat reduces SARS-COV-2 pulmonary infection in mouse models of COVID-19","volume":"12","author":"Li","year":"2021","journal-title":"MBio"},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.131324_bb0390","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1128\/AAC.36.7.1432","article-title":"Effects of protease inhibitors on replication of various myxoviruses","volume":"36","author":"Hosoya","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.131324_bb0395","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/infdis\/168.3.641","article-title":"Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in Ovo","volume":"168","author":"Hosoya","year":"1993","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0400","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pupt.2015.07.001","article-title":"The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells","volume":"33","author":"Yamaya","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.131324_bb0405","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.131324_bb0410","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the Split-protein-based cell-cell fusion assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0415","article-title":"COVID-19: famotidine, histamine, mast cells, and mechanisms","author":"Malone","year":"2020","journal-title":"Research Square (Research Square)."},{"issue":"12","key":"10.1016\/j.ijbiomac.2024.131324_bb0420","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1358\/dof.1992.017.12.193894","article-title":"Arbidol","volume":"17","author":"Glushkov","year":"1992","journal-title":"Drugs Future"},{"issue":"01","key":"10.1016\/j.ijbiomac.2024.131324_bb0425","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CD9.0000000000000014","article-title":"Antiviral Abidol is associated with the reduction of in-hospital mortality in COVID-19 patients","volume":"1","author":"Zeng","year":"2021","journal-title":"Cardiology Discovery"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.00249","article-title":"Effectiveness of Arbidol for COVID-19 prevention in health professionals","volume":"8","author":"Yang","year":"2020","journal-title":"Front. Public Health"},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.131324_bb0435","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11596-020-2203-3","article-title":"Potential of arbidol for post-exposure prophylaxis of COVID-19 transmission: A preliminary report of a retrospective cohort study","volume":"40","author":"Jin-Nong","year":"2020","journal-title":"Current Medical Science"},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.131324_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241896","article-title":"Clinical characteristics of re-positive COVID-19 patients in Huangshi, China: A retrospective cohort study","volume":"15","author":"Zhou","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.131324_bb0445","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/v13081665","article-title":"Antiviral activity of Umifenovir in vitro against a broad spectrum of coronaviruses, including the novel SARS-CoV-2 virus","volume":"13","author":"Leneva","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0450","series-title":"Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19. clinicaltrials.gov Report No.: NCT04422561 [Internet]","volume":"Aug","author":"Shouman","year":"2020"},{"issue":"February 16","key":"10.1016\/j.ijbiomac.2024.131324_bb0455","article-title":"Role of Ivermectin in the prevention of SARS-CoV-2 infection among healthcare Workers in India: A matched Case-control study","volume":"16, no. 2","author":"Behera","year":"2021","journal-title":"PLoS One"},{"issue":"January 1","key":"10.1016\/j.ijbiomac.2024.131324_bb0460","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/0028-3886.310073","article-title":"Sleep and Covid-19","volume":"69, no. 1","author":"Datta","year":"2021","journal-title":"Neurol. India"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0465","series-title":"Favipiravir Versus Arbidol for COVID-19: A Randomized Clinical Trial","volume":"March 20","author":"Chen","year":"2020"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0470","series-title":"Efficacy of Hydroxychloro-quine in Patients with COVID-19: Results of a Randomized Clinical Trial","volume":"March 30","author":"Chen","year":"2020"},{"issue":"April 9","key":"10.1016\/j.ijbiomac.2024.131324_bb0475","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000507639","article-title":"Mental health and psychosocial problems of medical health workers during the COVID-19 epidemic in China","volume":"89, no. 4","author":"Zhang","year":"2020","journal-title":"Psychother. Psychosom."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.131324_bb0480","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000507639","article-title":"Mental health and psychosocial problems of medical health workers during the COVID-19 epidemic in China","volume":"89","author":"Zhang","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0485","article-title":"The effects of social support on sleep quality of medical staff treating patients with coronavirus disease 2019 (COVID-19) in January and February 2020 in China","volume":"26","author":"Xiao","year":"2020","journal-title":"Medical science monitor: international medical journal of experimental and clinical research"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2020.101874","article-title":"Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19","volume":"110","author":"Singh","year":"2020","journal-title":"J. Chem. Neuroanat."},{"issue":"March 1","key":"10.1016\/j.ijbiomac.2024.131324_bb0495","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1080\/07391102.2020.1834457","article-title":"Structural Basis for the Inhibition of SARS-CoV2 Main Protease by Indian Medicinal Plant-Derived Antiviral Compounds","volume":"40, no. 5","author":"Saravanan","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0500","article-title":"Natural compounds as inhibitors of SARS-CoV-2 main protease (3CLpro): A molecular docking and simulation approach to combat COVID-19","volume":"26","author":"Rehman","year":"2021","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-74715-4","article-title":"Molecular docking study of potential phytochemicals and their effects on the complex of SARSCoV2 spike protein and human ACE2","volume":"10","author":"Basu","year":"2020","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.131324_bb0510","first-page":"4529","article-title":"In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking","volume":"24","author":"Joshi","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BSR20202583","article-title":"Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6","volume":"41","author":"Niu","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0520","article-title":"Comparative retrospective open-label study of ayurvedic medicines and their combination with allopathic drugs on asymptomatic and mildly-symptomatic COVID-19 patients","volume":"100472","author":"Balkrishna","year":"2021","journal-title":"Journal of Herbal Medicine"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0525","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13596-020-00508-9","article-title":"Matrix metalloproteinase inhibitors identified from Camellia sinensis for COVID-19 prophylaxis: an in silico approach","volume":"21","author":"Kanbarkar","year":"2021","journal-title":"Adv. Tradit. Med."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0530","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/srep01686","article-title":"Inhibition of novel b coronavirus replication by a combination of interferon-a2b and ribavirin","volume":"3","author":"Falzarano","year":"2013","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.131324_bb0535","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s11756-022-01012-y","article-title":"In silico studies on structural inhibition of SARS-CoV-2 main protease Mpro by major secondary metabolites of Andrographis paniculata and Cinchona officinalis","volume":"77","author":"Majumdar","year":"2022","journal-title":"Biologia (Bratisl)."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0540","article-title":"In silico study of coumarins and quinolines derivatives as potent inhibitors of SARS-CoV-2 main protease","volume":"8","author":"Yanez","year":"2020","journal-title":"Front. Chem"},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.131324_bb0545","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/molecules28010208","article-title":"In silico identification of anti-SARS-CoV-2 medicinal plants using cheminformatics and machine learning","volume":"28","author":"Liang","year":"2022","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.131324_bb0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240004","article-title":"In-silico design of a potential inhibitor of SARS-CoV-2 S protein","volume":"15","author":"Jaiswal","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0555","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s12640-022-00542-2","article-title":"A review of in silico research, SARS-CoV-2, and neurodegeneration: focus on papain-like protease","volume":"40","author":"Rieder","year":"2022","journal-title":"Neurotox. Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.131324_bb0560","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1021\/acsmedchemlett.8b00397","article-title":"Prediction of drug-target binding kinetics by comparative binding energy analysis","volume":"9","author":"Ganotra","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"20 June 28","key":"10.1016\/j.ijbiomac.2024.131324_bb0565","first-page":"10239","article-title":"Study of potentiality of dexamethasone and its derivatives against Covid-19","volume":"40","author":"Mitra","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1\u20133","key":"10.1016\/j.ijbiomac.2024.131324_bb0570","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.131324_bb0575","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/ndt\/gfi253","article-title":"Update on adverse drug events associated with parenteral iron","volume":"21","author":"Chertow","year":"2006","journal-title":"Nephrology Dialysis Trans- plantation"},{"issue":"12","key":"10.1016\/j.ijbiomac.2024.131324_bb0580","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1080\/07391102.2020.1871416","article-title":"Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods","volume":"40","author":"Chandra","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0585","series-title":"Life after COVID-19: Future directions? COVID-19 Pandemic","first-page":"211","author":"Amin","year":"2022"},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.131324_bb0590","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4103\/ijo.IJO_843_20","article-title":"COVID-19 pandemic: lessons learned and future directions","volume":"68","author":"Khanna","year":"2020","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.frl.2022.102801","article-title":"COVID-19 and the Economy: Summary of research and future directions","volume":"47","author":"Iyer","year":"2022","journal-title":"Financ. Res. Lett."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0600","series-title":"COVID-19 poses an unprecedented challenge to financial systems","author":"Rapid Development of Vacccines, Financial Crisis","year":"2024"},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.131324_bb0605","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41434-020-00209-7","article-title":"Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics","volume":"28","author":"Berber","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0610","article-title":"CRISPR-based surveillance for COVID-19 using genomically-comprehensive machine learning design","author":"Metsky","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0615","series-title":"A protocol for detection of COVID-19 using CRISPR diagnostics v.20200321","author":"Zhang","year":"2020"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0620","series-title":"Prediction of the SARSCoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, a","author":"Chen","year":"2024"},{"issue":"16","key":"10.1016\/j.ijbiomac.2024.131324_bb0625","doi-asserted-by":"crossref","first-page":"9121","DOI":"10.1039\/D0CS01065K","article-title":"A critical overview of computational approaches employed for COVID-19 drug discovery","volume":"50","author":"Muratov","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0630","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-1878-2_1","article-title":"Computational protein design methods for synthetic biology","volume":"1244","author":"Carbonell","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"6515","key":"10.1016\/j.ijbiomac.2024.131324_bb0635","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.abd9909","article-title":"De novo design of picomolar SARS-CoV-2 miniprotein inhibitors","volume":"370","author":"Cao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0640","unstructured":"Adapted from \u201cMechanism of SARS-CoV2 Viral Entry\u201d,\u201dSARS-CoV2 viral genome\u201d by BioRender.com (2023). Retrieved from https:\/\/app.biorender.com\/biorender-templates."},{"key":"10.1016\/j.ijbiomac.2024.131324_bb0645","author":"Reprinted from \u201cMechanism of SARS-CoV2 Viral Entry\u201d"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024021299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024021299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:54:10Z","timestamp":1731689650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813024021299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":129,"alternative-id":["S0141813024021299"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.131324","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An unprecedented global challenge, emerging trends and innovations in the fight against COVID-19: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.131324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"131324"}}